The
Cancer Genome Atlas project has completed the molecular characterization of several hundred glioblastoma tumors. These efforts have not only uncovered the extreme molecular complexity of glioblastoma but also identified several molecular targets that may play a role in glioblastoma growth.
Drugs to block many of these growth pathways are already available and can be repurposed for attacking glioblastoma. We support a precision medical approach in which these drugs are tested in patients whose tumors express each target.